Plain-English translation of NCT07124000 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is following about 100 patients across the United States who are starting treatment with (T-DXd) for advanced cancers that have a specific marker called HER2-positive. Researchers want to understand how well this medication works in real-world clinical practice—meaning in regular doctor's offices and hospitals, not just in controlled research settings. The study will track how patients respond to the treatment and how long they benefit from it.
Many patients with advanced cancers have already tried other treatments that didn't work well enough, and they need new options. This study aims to see whether this medication can help patients with a wider range of HER2-positive cancers who have few other choices, and to understand how it performs when used in everyday clinical care rather than in tightly controlled research trials.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as prescribed by your doctor in routine clinical practice at one of approximately 30 participating sites across the United States (including community oncology practices, hospital systems, and academic medical centers). Researchers will collect information about your treatment response, how long you benefit from the medication, when you might need to switch treatments, and what happens next in your care. This is an observational study, meaning doctors are tracking your real-world experience rather than assigning you to a specific experimental protocol.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States